ASH Annual Meeting & Exposition: Leukemia | Conference

Matthew S. Davids, MD, MMSc, spoke about the benefit of venetoclax combinations in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Lindsey Roeker, MD, spoke about identifying the correct population of patients with chronic lymphocytic leukemia who will benefit from umbralisib and ublituximab plus ibrutinib.

Matthew S. Davids, MD, MMSc, spoke about using venetoclax plus acalabrutinib in the phase 3 MAJIC study for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Lindsey Roeker, MD, spoke about phase 2 trial results which demonstrated efficacy of the combination of umbralisib and ublituximab added to ibrutinib for patients with chronic lymphocytic leukemia.

The combination of acalabrutinib, with or without obinutuzumab, produced a strong survival benefit for patients with treatment-naïve chronic lymphocytic leukemia over treatment with ibrutinib or venetoclax plus obinutuzumab.

Preclinical evidence supports further research in combining a menin inhibitor plus targeted therapies, as this may result in superior efficacy for patients with KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.

Lindsey Roeker, MD, spoke about using a combination that includes a Bruton tyrosine kinase inhibitor, PI3K inhibitor, and an anti-CD20 monoclonal antibody for patients with chronic lymphocytic leukemia.

A non inferiority design was presented at ASH 2021 for acalabrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia or small lymphocytic leukemia.

Jennifer A. Woyach, MD, spoke about why it’s important to use newer therapies instead of chemoimmunotherapy for patients with chronic lymphocytic leukemia.

Maintenance oral azacitidine produced a sustained survival benefit over placebo for patients with acute myeloid leukemia in first remission.